Abstract | BACKGROUND: METHODS: RESULTS: Positive accumulation of (99m) Tc-MIBI in tumors was observed in 76 patients (88.4%). The tumor response was a complete response (CR) in 8 patients, a partial response (PR) in 68 patients, stable disease (SD) in 9 patients, and progressive disease (PD) in 1 patient. The response rate (CR and PR) to 5-FU/DDP chemotherapy in patients who had positive (99m) Tc-MIBI accumulation ( tumor uptake ratio [TUR] >1.1) was higher than that in patients who had negative (99m) Tc-MIBI accumulation (TUR ≤ 1.1; 98.7% vs 10%; P < .001). CONCLUSIONS:
|
Authors | Xiao Shen Wang, Ying Jian Zhang, Xiao Lan Liu, Zheng Rong Zhou, Chao Su Hu, Avraham Eisbruch |
Journal | Cancer
(Cancer)
Vol. 117
Issue 11
Pg. 2435-41
(Jun 01 2011)
ISSN: 1097-0142 [Electronic] United States |
PMID | 24048791
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2010 American Cancer Society. |
Chemical References |
- Antineoplastic Agents
- Technetium Tc 99m Sestamibi
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Carcinoma
- Drug Resistance, Neoplasm
- Female
- Humans
- Male
- Middle Aged
- Nasopharyngeal Carcinoma
- Nasopharyngeal Neoplasms
(diagnosis, drug therapy)
- Neoadjuvant Therapy
- Neoplasm Staging
- Prognosis
- Technetium Tc 99m Sestamibi
- Tomography, Emission-Computed, Single-Photon
- Treatment Outcome
- Young Adult
|